Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer
Top Cited Papers
Open Access
- 18 May 2004
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 90 (12), 2312-2316
- https://doi.org/10.1038/sj.bjc.6601814
Abstract
Interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) are important multifunctional cytokines involved in tumour growth and metastasis. In this study, we have measured serial levels of serum IL-6 and TNF-α in prostate cancer patients. A total of 80 patients with carcinoma of the prostate and 38 controls were studied. Three patient groups, with small bulk localised, large volume localised and metastatic prostate cancer, were assessed. Serum IL-6 and TNF-α levels were measured and correlated with clinicopathological variables and patient survival. Serial changes in these cytokines were also assessed and related to disease progression in 40 patients with recurrent prostate cancer. Serum IL-6 levels in patients with metastatic disease (9.3±7.8 pg ml−1) were higher than those in patients with localised disease (1.3±0.8 pg ml−1, Pα were found in metastatic disease (6.3±3.6 pg ml−1) compared with localised disease (1.1±0.5 pg ml−1, Pα correlate with the extent of disease in patients with prostate cancer and may be monitored in conjunction with other disease markers.Keywords
This publication has 26 references indexed in Scilit:
- Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progressionThe Prostate, 2002
- Bloodborne biomolecular markers in prostate cancer development and progressionNature Reviews Cancer, 2002
- Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor CellsMolecular and Cellular Biology, 2001
- TUMOR NECROSIS FACTOR-α REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINEJournal of Urology, 2000
- CYTOKINE VARIATIONS IN PATIENTS WITH HORMONE TREATED PROSTATE CANCERJournal of Urology, 2000
- CYTOKINE VARIATIONS IN PATIENTS WITH HORMONE TREATED PROSTATE CANCERJournal of Urology, 2000
- TUMOR NECROSIS FACTOR-?? REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINEJournal of Urology, 2000
- ELEVATED LEVELS OF CIRCULATING INTERLEUKIN-6 AND TRANSFORMING GROWTH FACTOR-beta 1 IN PATIENTS WITH METASTATIC PROSTATIC CARCINOMAJournal of Urology, 1999
- Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.Oncology Reports, 1998
- Interleukin-6: A candidate mediator of human prostate cancer morbidityUrology, 1995